Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000338910 | SCV000345905 | uncertain significance | not provided | 2018-06-05 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000764464 | SCV000895529 | uncertain significance | Renal-hepatic-pancreatic dysplasia 1; Nephronophthisis 3; NPHP3-related Meckel-like syndrome | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000799611 | SCV000939282 | likely benign | Nephronophthisis | 2025-01-01 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000338910 | SCV005410409 | uncertain significance | not provided | 2024-05-15 | criteria provided, single submitter | clinical testing | BS1 |
Prevention |
RCV004543152 | SCV004790364 | uncertain significance | NPHP3-related disorder | 2024-09-25 | no assertion criteria provided | clinical testing | The NPHP3 c.3896G>A variant is predicted to result in the amino acid substitution p.Gly1299Asp. This variant has been reported in the homozygous state in an individual with congenital heart defects (Jin et al. 2017. PubMed ID: 28991257). This variant is reported in 0.13% of alleles in individuals of Latino descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |